We are a privately held, late clinical-stage biopharmaceutical company that is focused on identifying and developing therapies for patients suffering from serious gastrointestinal (GI) diseases. We believe that the lack of innovation and limited treatment options for GI patients present us with a significant opportunity to address this large unmet medical need. Initially, we are focused on pursuing indications for the treatment of patients suffering from erosive esophagitis (EE) and gastroparesis. We believe our approach, which is targeted to the gastroenterology community, combined with the experience of our management team in developing and commercializing medicines in the GI space, positions us to identify, develop and efficiently bring to market solutions for GI diseases with limited innovation and/or treatment options.